SCHEMBL546240

SCHEMBL546240

O=c1ccoc2cc(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 3/20 1.00
KDM4E B2RXH2 4/20 0.56
MAOA P21397 5/20 0.53
MAOB P27338 5/20 0.53
GRM5 P41594 1/20 0.51
CYP19A1 P11511 4/20 0.50
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
HSD17B10 Q99714 3/20 0.50
CYP3A4 P08684 3/20 0.50
HPGD P15428 3/20 0.50
AKR1B1 P15121 2/20 0.50
MPO P05164 1/20 0.50
MAPK1 P28482 1/20 0.50
QPCT Q16769 1/20 0.50
IP6K2 Q9UHH9 1/20 0.50
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
CA12 O43570 2/20 0.49
AKR1B10 O60218 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799642 1.00 FTO (1.00) FTOKDM4EMAOAMAOBGRM5
Methylene Chloride SCHEMBL27891472 0.94 FTO (0.89) FTOKDM4EMAOAMAOBGRM5
SCHEMBL7617877 0.84 FTO (0.72) FTOMAOAMAOBALDH1A1SMN1; SMN2
Ethoxycarbonyl Group SCHEMBL27476972 0.82 FTO (0.68) FTOKDM4EMAOAMAOBGRM5
SCHEMBL15346102 0.79 FTO (0.66) FTOKDM4EMAOAMAOBGRM5
SCHEMBL28230155 0.78 FTO (0.63) FTOKDM4EMAOAMAOBGRM5
SCHEMBL3681299 0.76 FTO (0.61) FTOKDM4EMAOAMAOBGRM5
SCHEMBL30771801 0.76 FTO (0.61) FTOKDM4EMAOAMAOBGRM5
SCHEMBL17708837 0.76 FTO (0.61) FTOKDM4EMAOAMAOBGRM5
SCHEMBL903208 0.76 FTO (0.61) FTOKDM4EMAOAMAOBGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12594421-B2 Compositions and methods for increasing cancer cell sensitivity to alternating electric fields NOVOCURE GMBH (CH) 2026-04-07 US claimed
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO LLC (US) 2026-04-02 US claimed
EP-4583856-A2 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS Native Code Bio, LLC (US) 2025-07-16 EP claimed
CN-116239557-B Compound containing 7-hydroxy chromone structure and preparation method and application thereof 深圳万知达企业管理有限公司 2025-02-18 CN claimed
WO-2024182413-A1 THERAPEUTIC METHODS SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) 2024-09-06 WO claimed
WO-2024054688-A2 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO, LLC (US) 2024-03-14 WO claimed
CN-116239557-A Compound containing 7-hydroxy chromone structure and preparation method and application thereof 广东轻工职业技术学院 2023-06-09 CN claimed
EP-4188380-A1 COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS Novocure GmbH (CH) 2023-06-07 EP claimed
US-20220096818-A1 Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields BIOPHARMA CREDIT PLC (GB) 2022-03-31 US claimed
WO-2022029628-A1 COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS NOVOCURE GMBH (CH) 2022-02-10 WO claimed
US-20080003300-A1 Compostions containing Mg/Zn/F-CaP plus inhibitors of pro-inflammatory Cytokines (a combination of a Free-B-Ring flavonoids and a flavan) for osteoporosis prevention, therapy and treatment of bone diseases GAFFAR MARIA C 2008-01-03 US claimed
CN-101083981-A Flavonoid composition for treating oral diseases UNIGEN PHARMACEUTICALS INC (US) 2007-12-05 CN claimed
EP-1804787-A2 FLAVONOID COMPOSITION FOR TREATING ORAL DISEASES Unigen Pharmaceuticals, Inc. (US) 2007-07-11 EP claimed
WO-2006045056-A2 FLAVONOID COMPOSITION FOR TREATING ORAL DISEASES UNIGEN PHARMACEUTICALS, INC. (US) 2006-04-27 WO claimed
US-20060079467-A1 administering plants extracts which inhibits cyclooxygenases and lipoxygenases, and reduces cytokine production; periodontal diseases UNIGEN PHARMACEUTICALS, INC. (US) 2006-04-13 US claimed
US-20050164957-A1 7-Hydroxy chromones as potent antioxidants UNIGEN PHARMACEUTICALS, INC. (US) 2005-07-28 US claimed
US-6884783-B2 7-Hydroxy chromones as potent antioxidants UNIGEN PHARMACEUTICALS, INC. (US) 2005-04-26 US claimed
EP-1503777-A1 7-HYDROXY CHROMONES AS POTENT ANTIOXIDANTS Unigen Pharmaceuticals, Inc. (US) 2005-02-09 EP claimed
WO-2003092713-A1 7-HYDROXY CHROMONES AS POTENT ANTIOXIDANTS UNIGEN PHARMACEUTICALS, INC. (US) 2003-11-13 WO claimed
US-20030207818-A1 Identification and purification of 7-hydroxychromes that exhibit potent antioxidant activity. In one embodiment the present invention includes a method for providing an antioxidant to a host in need thereof, comprising UNIGEN, INC. 2003-11-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080003300-A1 Compostions containing Mg/Zn/F-CaP plus inhibitors of pro-inflammatory Cytokines (a combination of a Free-B-Ring flavonoids and a flavan) for osteoporosis prevention, therapy and treatment of bone diseases IL1B, TNF, SLC30A6 FTO 4044/4885KDM4E 4405/4885MAOA 347/4885
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS HMBS, SNCA, PYGB FTO 117/4885KDM4E 1322/4885MAOA 229/4885
US-20060079467-A1 administering plants extracts which inhibits cyclooxygenases and lipoxygenases, and reduces cytokine production; periodontal diseases LPO, GLA, LOX FTO 3580/4885KDM4E 3660/4885MAOA 200/4885
US-12594421-B2 Compositions and methods for increasing cancer cell sensitivity to alternating electric fields PTK2, GSK3B, MTOR FTO 2908/4885KDM4E 2098/4885MAOA 4340/4885
US-20030207818-A1 Identification and purification of 7-hydroxychromes that exhibit potent antioxidant activity. In one embodiment the present invention includes a method for providing an antioxidant to a host in need thereof, comprising NQO1, KEAP1, NOX4 FTO 407/4885KDM4E 2040/4885MAOA 269/4885
US-20050164957-A1 7-Hydroxy chromones as potent antioxidants CYP27A1, NOX4, ROS1 FTO 1117/4885KDM4E 2448/4885MAOA 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.